Literature for peptidase M14.009: carboxypeptidase B2

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, P Specificity, K Knockout, E Expression, V Review, M Mutation, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2025

Maruo,K., Tsubota,M., Tajima,K., Matsunaga,H., Sekiguchi,F., Minami,T., Ito,A., Tomono,Y., Nishibori,M. and Kawabata,A. Thrombomodulin-Induced Prevention of Peripheral Neuropathy in Oxaliplatin-Treated Mice Involves Complement C5a Inactivation and PAR1 Activation in Addition To HMGB1 Degradation J Neuroimmune Pharmacol (2025) 20, 100-100. PubMed Europe PubMed DOI

2023

Aksakal,A., Kilic,A.F., Afsin,D.E., Baygutalp,N.K. and Kerget,B. Evaluation of the relationship between TAFI level and prognosis in COVID-19 patients Eur Rev Med Pharmacol Sci (2023) 27, 4764-4771. PubMed Europe PubMed DOI

2021

Schaffner,A.P., Sansilvestri-Morel,P., Despaux,N., Ruano,E., Persigand,T., Rupin,A., Mennecier,P., Vallez,M.O., Raimbaud,E., Desos,P. and Gloanec,P. Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) J Med Chem (2021) 64, 3897-3910. PubMed Europe PubMed DOI
Sillen,M. and Declerck,P.J. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review Int J Mol Sci (2021) 22 PubMed Europe PubMed DOI PMC EPMC
Wheeler,J.X., Thelwell,C., Rigsby,P. and Whiting,G. Quantitation of thrombin-activatable fibrinolysis inhibitor in human plasma by isotope dilution mass spectrometry Anal Biochem (2021) , 114413-114413. PubMed Europe PubMed DOI
Zhou,Q., Zhao,L., Shao,Z., Declerck,P., Leung,L.L.K. and Morser,J. Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice J Thromb Haemost (2021) 20, 238-244. PubMed Europe PubMed DOI

2020

Mertens,J.C., Boisseau,W., Leenaerts,D., Di Meglio,L., Loyau,S., Lambeir,A.M., Ducroux,C., Jandrot-Perrus,M., Michel,J.B., Mazighi,M., Hendriks,D. and Desilles,J.P. Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke J Thromb Haemost (2020) PubMed Europe PubMed DOI I
Minami,T., Takeda,M., Sata,M., Kato,H., Yano,K., Sakai,T., Tsujita,R., Kawasaki,K. and Ito,A. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity Eur J Pharmacol (2020) 880, 173196-173196. PubMed Europe PubMed DOI
Nougier,C., Benoit,R., Simon,M., Desmurs-Clavel,H., Marcotte,G., Argaud,L., David,J.S., Bonnet,A., Negrier,C. and Dargaud,Y. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis J Thromb Haemost (2020) PubMed Europe PubMed DOI PMC EPMC
Pedersen,N.B., Stolberg,C.R., Mundbjerg,L.H., Juhl,C.B., Gram,B., Funch-Jensen,P., de Maat,M.P.M., Munster,A.B. and Bladbjerg,E.M. Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery Clin Obes (2020) , e12397-e12397. PubMed Europe PubMed DOI
Sanda,T., Yoshimura,M., Hyodo,K., Ishii,H. and Yamashita,T. Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE(-/-)-LDLR(-/-) Double-Knockout Mice Korean Circ J (2020) 50, 804-816. PubMed Europe PubMed DOI I
Suzuki,Y., Sano,H., Mochizuki,L., Honkura,N. and Urano,T. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system Blood Adv (2020) 4, 5501-5511. PubMed Europe PubMed DOI PMC EPMC

2018

Arauz,A., Arguelles,N., Jara,A., Guerrero,J. and Barboza,M.A. Thrombin-activatable fibrinolysis inhibitor polymorphisms and cerebral venous thrombosis in Mexican Mestizo patients Clin Appl Thromb Hemost (2018) 24, 1291-1296. PubMed Europe PubMed DOI M
ElDanasori,N., Abulata,N., Shaheen,I.A., Elgendy,A.M. and El-Khayat,W. Thrombin-activatable fibrinolysis inhibitor gene polymorphism (TAFI1040C/T) in women with recurrent spontaneous abortion Clin Appl Thromb Hemost (2018) 24, 532-535. PubMed Europe PubMed DOI M
Ito,Y., Noguchi,K., Morishima,Y. and Yamaguchi,K. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor Blood Coagul Fibrinolysis (2018) 29, 314-321. PubMed Europe PubMed DOI K I
Itoh,T., Yoshimoto,N., Hirano,Y. and Yamamoto,K. Structural basis for the selective inhibition of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) by a selenium-containing inhibitor with chloro-aminopyridine as a basic group Bioorg Med Chem Lett (2018) 28, 2256-2260. PubMed Europe PubMed DOI S I
Leenaerts,D., Loyau,S., Mertens,J.C., Boisseau,W., Michel,J.B., Lambeir,A.M., Jandrot-Perrus,M. and Hendriks,D. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models J Thromb Haemost (2018) 16, 2057-2069. PubMed Europe PubMed DOI I
Leung,L.L.K. and Morser,J. Carboxypeptidase B2 and carboxypeptidase N in the cross-talk between coagulation, thrombosis, inflammation and innate immunity J Thromb Haemost (2018) PubMed Europe PubMed DOI
Morser,J., Shao,Z., Nishimura,T., Zhou,Q., Zhao,L., Higgins,J. and Leung,L.L.K. Carboxypeptidase B2 and N play different roles in regulation of activated complements C3a and C5a in mice J Thromb Haemost (2018) 16, 991-1002. PubMed Europe PubMed DOI K

2017

Gurewich,V. and Pannell,R. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects: Comment J Thromb Haemost (2017) 15, 2080-2081. PubMed Europe PubMed DOI I
Leenaerts,D., Aernouts,J., Van der Veken,P., Sim,Y., Lambeir,A.M. and Hendriks,D. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis Thromb Haemost (2017) 117, 1498-1508. PubMed Europe PubMed DOI
Zhou,J., Kochan,J., Yin,O., Warren,V., Zamora,C., Atiee,G., Pav,J., Orihashi,Y., Vashi,V. and Dishy,V. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects J Thromb Haemost (2017) 15, 961-971. PubMed Europe PubMed DOI I

2016

Bazzi,Z.A., Lanoue,D., El-Youssef,M., Romagnuolo,R., Tubman,J., Cavallo-Medved,D., Porter,L.A. and Boffa,M.B. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis BMC Cancer (2016) 16, 328-328. PubMed Europe PubMed DOI PMC EPMC
Denorme,F., Wyseure,T., Peeters,M., Vandeputte,N., Gils,A., Deckmyn,H., Vanhoorelbeke,K., Declerck,P.J. and De Meyer,S.F. Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice Stroke (2016) 47, 2419-2422. PubMed Europe PubMed DOI
Gurewich,V. and Pannell,R. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor: comment J Thromb Haemost (2016) 14, 1899-1900. PubMed Europe PubMed DOI
Halland,N., Czech,J., Czechtizky,W., Evers,A., Follmann,M., Kohlmann,M., Schreuder,H.A. and Kallus,C. Sulfamide as zinc binding motif in small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) J Med Chem (2016) 59, 9567-9573. PubMed Europe PubMed DOI S I
Plug,T. and Meijers,J.C. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor J Thromb Haemost (2016) 14, 633-644. PubMed Europe PubMed DOI V
Schreuder,H., Liesum,A., Lonze,P., Stump,H., Hoffmann,H., Schiell,M., Kurz,M., Toti,L., Bauer,A., Kallus,C., Klemke-Jahn,C., Czech,J., Kramer,D., Enke,H., Niedermeyer,T.H., Morrison,V., Kumar,V. and Bronstrup,M. Isolation, co-crystallization and structure-based characterization of anabaenopeptins as highly potent inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) Sci Rep (2016) 6, 32958-32958. PubMed Europe PubMed DOI PMC EPMC I
Tawara,S., Sakai,T. and Matsuzaki,O. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin Thromb Res (2016) 147, 72-79. PubMed Europe PubMed DOI
Zhou,X., Weeks,S.D., Ameloot,P., Callewaert,N., Strelkov,S.V. and Declerck,P.J. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity J Thromb Haemost (2016) 14, 1629-1638. PubMed Europe PubMed DOI I

2015

Atkinson,J.M., Pullen,N., Da Silva-Lodge,M., Williams,L. and Johnson,T.S. Inhibition of thrombin-activated fibrinolysis inhibitor increases survival in experimental kidney fibrosis J Am Soc Nephrol (2015) 26, 1925-1937. PubMed Europe PubMed DOI I
Halland,N., Bronstrup,M., Czech,J., Czechtizky,W., Evers,A., Follmann,M., Kohlmann,M., Schiell,M., Kurz,M., Schreuder,H.A. and Kallus,C. Novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) from natural product anabaenopeptin J Med Chem (2015) 58, 4839-4844. PubMed Europe PubMed DOI I
Plug,T. and Meijers,J.C.M. New clues regarding the mysterious mechanism of activated thrombin-activatable fibrinolysis inhibitor self-destruction J Thromb Haemost (2015) 13, 1081-1083. PubMed Europe PubMed DOI
Plug,T., Marquart,J.A., Marx,P.F. and Meijers,J.C. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides J Thromb Haemost (2015) 13, 2093-2101. PubMed Europe PubMed DOI
Shao,Z., Nishimura,T., Leung,L.L. and Morser,J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model J Thromb Haemost (2015) 13, 1090-1102. PubMed Europe PubMed DOI K
Zheng,C., Li,X., Kong,C., Ke,S., Peng,C., Cui,T., Gao,M., Zhou,Y., Guo,W., Huang,L., Petersen,R.B. and Huang,K. Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease Blood Coagul Fibrinolysis (2015) 26, 185-190. PubMed Europe PubMed DOI M
Zhou,X. and Declerck,P.J. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation J Thromb Haemost (2015) 13, 1084-1089. PubMed Europe PubMed DOI

2014

Brink,M., Dahlen,A., Olsson,T., Polla,M. and Svensson,T. Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa) Bioorg Med Chem (2014) 22, 2261-2268. PubMed Europe PubMed DOI S I
He,F.-M., Pan,J.-G., Zhao,X.-Y., Yuan,H., Mou,X. and Chen,Y.-S. Correlation between C1040T and G753A polymorphisms in the gene encoding region of thrombin-activatable fibrinolysis inhibitor and cerebral infarction Chin J Cerebrovasc Dis (2014) 11, 347-353. DOI M
Kovacs,A., Szabo,L., Longstaff,C., Tenekedjiev,K., Machovich,R. and Kolev,K. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin Thromb Res (2014) 133, 80-87. PubMed Europe PubMed DOI
Lepus,C.M., Song,J.J., Wang,Q., Wagner,C.A., Lindstrom,T.M., Chu,C.R., Sokolove,J., Leung,L.L. and Robinson,W.H. Brief report: carboxypeptidase B serves as a protective mediator in osteoarthritis Arthritis Rheum (2014) 66, 101-106. PubMed Europe PubMed DOI
Philippou,H. Thrombin activatable fibrinolysis inhibitor (TAFI): More complex when it meets the clot Thromb Res (2014) 133, 1-2. PubMed Europe PubMed DOI
Plug,T., Kramer,G. and Meijers,J.C. A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor J Thromb Haemost (2014) 12, 1717-1725. PubMed Europe PubMed DOI
Santos,I.R., Fernandes,A.P., Carvalho,M.G., Sousa,M.O., Ferreira,C.N. and Gomes,K.B. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects Clin Chim Acta (2014) 433, 76-83. PubMed Europe PubMed DOI M
Shi,J., Zhi,P., Chen,J., Wu,P. and Tan,S. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis Thromb Res (2014) 134, 610-616. PubMed Europe PubMed DOI M

2013

Chengwei,X., Xiaoli,M., Yuan,Z., Li,P., Shengjiang,W., Chao,Y. and Yunshan,W. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer Blood Coagul Fibrinolysis (2013) 24, 698-703. PubMed Europe PubMed DOI M
Fernandez,D., Pallares,I., Covaleda,G., Aviles,F.X. and Vendrell,J. Metallocarboxypeptidases and their Inhibitors: Recent Developments in Biomedically Relevant Protein and Organic Ligands Curr Med Chem (2013) 20, 1595-1608. PubMed Europe PubMed V S I
Foley,J.H., Kim,P.Y., Mutch,N.J. and Gils,A. Insights into thrombin activatable fibrinolysis inhibitor function and regulation J Thromb Haemost (2013) 11 Suppl 1, 306-315. PubMed Europe PubMed DOI
Garand,M., Lin,J.H., Zagorac,B., Koschinsky,M.L. and Boffa,M.B. Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone Blood Coagul Fibrinolysis (2013) 24, 393-404. PubMed Europe PubMed DOI
Vercauteren,E., Gils,A. and Declerck,P.J. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis Semin Thromb Hemost (2013) 39, 365-372. PubMed Europe PubMed DOI T
Woodman,I. Osteoarthritis: carboxypeptidase B inhibits complement and cartilage loss Nat Rev Rheumatol (2013) 9, 697-697. PubMed Europe PubMed DOI

2012

Colucci,M. and Semeraro,N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation Thromb Res (2012) 129, 314-319. PubMed Europe PubMed DOI
Fujiwara,A., Taguchi,O., Takagi,T., D'Alessandro-Gabazza,C.N., Boveda-Ruiz,D., Toda,M., Yasukawa,A., Matsushima,Y., Miyake,Y., Kobayashi,H., Kobayashi,T., Gil-Bernabe,P., Naito,M., Yoshida,M., Morser,J., Takei,Y. and Gabazza,E.C. Role of thrombin-activatable fibrinolysis inhibitor in allergic bronchial asthma Lung (2012) 190, 189-198. PubMed Europe PubMed DOI K
Hendriks,D.F. Carboxypeptidase U [ISSN:978-0-12-407744-7] (2012) 3, 1321-1324. DOI
Mishra,N., Buelens,K., Theyskens,S., Compernolle,G., Gils,A. and Declerck,P.J. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis J Thromb Haemost (2012) 10, 1091-1099. PubMed Europe PubMed DOI
Xu,C.W., Wu,X.B., Ma,X.L., Wang,Y.S., Zhang,B.C., Zhao,J.J., Wang,Z.J. and Chen,J. Genetic variation in thrombin-activatable fibrinolysis inhibitor is associated with the risk of diabetic nephropathy J Endocrinol Invest (2012) 35, 620-624. PubMed Europe PubMed DOI M
Yoshimoto,N., Sasaki,T., Sugimoto,K., Ishii,H. and Yamamoto,K. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease J Med Chem (2012) 55, 7696-7705. PubMed Europe PubMed DOI I

2011

Declerck,P.J. Thrombin activatable fibrinolysis inhibitor Hamostaseologie (2011) 31, 165-173. PubMed Europe PubMed DOI V
Foley,J.H., Cook,P.F. and Nesheim,M.E. Kinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sites J Biol Chem (2011) 286, 19280-19286. PubMed Europe PubMed DOI P
Heylen,E., Willemse,J.L. and Hendriks,D.F. Comparative study of commercially available procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) assays J Thromb Haemost (2011) 9, 1407-1409. PubMed Europe PubMed DOI A
Heylen,E., Willemse,J. and Hendriks,D. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis Front Biosci (2011) 16, 2427-2450. PubMed Europe PubMed DOI V
Mishra,N., Vercauteren,E., Develter,J., Bammens,R., Declerck,P.J. and Gils,A. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms Thromb Haemost (2011) 106, 90-101. PubMed Europe PubMed DOI
Valls Seron,M., Plug,T., Marquart,J.A., Marx,P.F., Herwald,H., DE Groot,P.G. and Meijers,J.C. Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B Thromb Haemost (2011) 106, 609-616. PubMed Europe PubMed DOI

2010

Buelens,K., Hassanzadeh-Ghassabeh,G., Muyldermans,S., Gils,A. and Declerck,P.J. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor J Thromb Haemost (2010) 8, 1302-1312. PubMed Europe PubMed DOI
Heylen,E., Van Goethem,S., Willemse,J., Olsson,T., Augustyns,K. and Hendriks,D. Development of a sensitive and selective assay for the determination of procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) in plasma Anal Biochem (2010) 396, 152-154. PubMed Europe PubMed DOI A
Heylen,E., Van Goethem,S., Augustyns,K. and Hendriks,D. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: challenges overcome by a novel selective assay Anal Biochem (2010) 403, 114-116. PubMed Europe PubMed DOI A
Ieko,M., Yoshida,M., Naito,S., Nakabayashi,T., Kanazawa,K., Mizukami,K., Mukai,M., Atsumi,T. and Koike,T. Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation Int J Hematol (2010) 91, 776-783. PubMed Europe PubMed DOI
Jessen,L.R., Wiinberg,B., Kjelgaard-Hansen,M., Jensen,A.L., Rozanski,E. and Kristensen,A.T. Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs Vet Clin Pathol (2010) 39, 296-301. PubMed Europe PubMed DOI
Joanna,D. and Wojciech,W. The role of thrombin-activatable fibrinolysis inhibitor in the pathophysiology of hemostasis Adv Clin Exp Med (2010) 19, 379-387.
Kozian,D.H., Lorenz,M., Marz,W., Cousin,E., Mace,S. and Deleuze,J.F. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study Thromb Haemost (2010) 103, 976-983. PubMed Europe PubMed DOI M
Kraft,P., Schwarz,T., Meijers,J.C., Stoll,G. and Kleinschnitz,C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke PLoS ONE (2010) 5, e11658-e11658. PubMed Europe PubMed DOI PMC EPMC K
Miljic,P., Heylen,E., Willemse,J., Djordjevic,V., Radojkovic,D., Colovic,M., Elezovic,I. and Hendriks,D. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis Srp Arh Celok Lek (2010) 138 Suppl 1, 74-78. PubMed Europe PubMed
Morser,J., Gabazza,E.C., Myles,T. and Leung,L.L. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost (2010) 8, 868-876. PubMed Europe PubMed DOI K
Pruner,I., Djordjevic,V., Miljic,P., Kovac,M., Antonijevic,N., Rakicevic,L. and Radojkovic,D. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss Blood Coagul Fibrinolysis (2010) 21, 679-682. PubMed Europe PubMed DOI M
Qin,L., D'Alessandro-Gabazza,C.N., Aoki,S., Gil-Bernabe,P., Yano,Y., Takagi,T., Boveda-Ruiz,D., Ramirez Marmol,A.Y., San Martin Montenegro,V.T., Toda,M., Miyake,Y., Taguchi,O., Takei,Y., Morser,J. and Gabazza,E.C. Pulmonary hypertension is ameliorated in mice deficient in thrombin-activatable fibrinolysis inhibitor J Thromb Haemost (2010) 8, 808-816. PubMed Europe PubMed DOI K
Sanglas,L., Arolas,J.L., Valnickova,Z., Aviles,F.X., Enghild,J.J. and Gomis-Ruth,F.X. Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor J Thromb Haemost (2010) 8, 1056-1065. PubMed Europe PubMed DOI
Schultz,G., Tedesco,M.M., Sho,E., Nishimura,T., Sharif,S., Du,X., Myles,T., Morser,J., Dalman,R.L. and Leung,L.L. Enhanced abdominal aortic aneurysm formation in thrombin-activatable procarboxypeptidase B-deficient mice Arterioscler Thromb Vasc Biol (2010) 30, 1363-1370. PubMed Europe PubMed DOI K
Valls Seron,M., Haiko,J., DE Groot,P.G., Korhonen,T.K. and Meijers,J.C. Thrombin-activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis J Thromb Haemost (2010) 8, 2232-2240. PubMed Europe PubMed DOI
Valnickova,Z., Sanglas,L., Arolas,J.L., Petersen,S.V., Schar,C., Otzen,D., Aviles,F.X., Gomis-Ruth,F.X. and Enghild,J.J. Flexibility of the thrombin-activatable fibrinolysis inhibitor pro-domain enables productive binding of protein substrates J Biol Chem (2010) 285, 38243-38250. PubMed Europe PubMed DOI S

2009

Brouns,R., Heylen,E., Sheorajpanday,R., Willemse,J.L., Kunnen,J., De Surgeloose,D., Hendriks,D.F. and De Deyn,P.P. Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients Clin Neurol Neurosurg (2009) 111, 165-170. PubMed Europe PubMed DOI
de Bruijne,E.L., Gils,A., Guimaraes,A.H., Dippel,D.W., Deckers,J.W., van den Meiracker,A.H., Poldermans,D., Rijken,D.C., Declerck,P.J., de Maat,M.P. and Leebeek,F.W. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study J Thromb Haemost (2009) 7, 919-927. PubMed Europe PubMed DOI
Dempfle,C.E. and Borggrefe,M. Thrombin-activatable fibrinolysis inhibitor-A inhibitors: drugs for sepsis or drugs for disseminated intravascular coagulation? Crit Care Med (2009) 37, 1823-1824. PubMed Europe PubMed DOI I
Develter,J., Dewilde,M., Gils,A. and Declerck,P.J. Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor Thromb Haemost (2009) 102, 69-75. PubMed Europe PubMed DOI
Du,X.Y., Zabel,B.A., Myles,T., Allen,S.J., Handel,T.M., Lee,P.P., Butcher,E.C. and Leung,L.L. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets J Biol Chem (2009) 284, 751-758. PubMed Europe PubMed DOI PMC EPMC
Marx,P.F., Plug,T., Havik,S.R., Morgelin,M. and Meijers,J.C. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J Thromb Haemost (2009) 7, 445-452. PubMed Europe PubMed DOI
Marx,P.F., Verkleij,C.J., Seron,M.V. and Meijers,J.C. Recent developments in thrombin-activatable fibrinolysis inhibitor research Mini Rev Med Chem (2009) 9, 1165-1173. PubMed Europe PubMed DOI V
Meltzer,M.E., Doggen,C.J., DE Groot,P.G., Meijers,J.C., Rosendaal,F.R. and Lisman,T. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men Haematologica (2009) 94, 811-818. PubMed Europe PubMed DOI PMC EPMC
Miah,M.F. and Boffa,M.B. Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin J Thromb Haemost (2009) 7, 665-672. PubMed Europe PubMed DOI
Muto,Y., Suzuki,K., Iida,H., Sakakibara,S., Kato,E., Itoh,F., Kakui,N. and Ishii,H. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats Crit Care Med (2009) 37, 1744-1749. PubMed Europe PubMed DOI I
Okumura,N., Koh,T., Hasebe,Y., Seki,T. and Ariga,T. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture J Biol Chem (2009) 284, 16553-16561. PubMed Europe PubMed DOI PMC EPMC
Sharif,S.A., Du,X., Myles,T., Song,J.J., Price,E., Lee,D.M., Goodman,S.B., Nagashima,M., Morser,J., Robinson,W.H. and Leung,L.L. Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis Arthritis Rheum (2009) 60, 2902-2912. PubMed Europe PubMed DOI
Tassies,D., Roque,M., Monteagudo,J., Martorell,T., Sionis,A., Arzamendi,D., Heras,M. and Reverter,J.C. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome Thromb Res (2009) 124, 614-618. PubMed Europe PubMed DOI M
Tregouet,D.A., Schnabel,R., Alessi,M.C., Godefroy,T., Declerck,P.J., Nicaud,V., Munzel,T., Bickel,C., Rupprecht,H.J., Lubos,E., Zeller,T., Juhan-Vague,I., Blankenberg,S., Tiret,L. and Morange,P.E. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study J Thromb Haemost (2009) 7, 49-57. PubMed Europe PubMed DOI
Valnickova,Z., Thaysen-Andersen,M., Hojrup,P., Christensen,T., Sanggaard,K.W., Kristensen,T. and Enghild,J.J. Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI) BMC Biochem (2009) 10, 13-13. PubMed Europe PubMed DOI PMC EPMC
Willemse,J.L., Heylen,E., Nesheim,M.E. and Hendriks,D.F. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? J Thromb Haemost (2009) 7, 1962-1971. PubMed Europe PubMed DOI V
Wu,C., Kim,P.Y., Manuel,R., Seto,M., Whitlow,M., Nagashima,M., Morser,J., Gils,A., Declerck,P. and Nesheim,M.E. The roles of selected arginine and lysine residues of TAFI (pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex J Biol Chem (2009) 284, 7059-7067. PubMed Europe PubMed DOI PMC EPMC

2008

Akinci,B. and Yesil,S. Role of thrombin activatable fibrinolysis inhibitor in endocrine and cardiovascular disorders Recent Pat Endocr Metab Immune Drug Discov (2008) 2, 57-61.
Anand,K., Pallares,I., Valnickova,Z., Christensen,T., Vendrell,J., Wendt,K.U., Schreuder,H.A., Enghild,J.J. and Aviles,F.X. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa J Biol Chem (2008) 283, 29416-29423. PubMed Europe PubMed DOI PMC EPMC S
Biscetti,F. Glycosylation of thrombin activatable fibrinolysis inhibitor: why is it so important? Circ Res (2008) 102, 278-279. PubMed Europe PubMed DOI
Biswas,A., Tiwari,A.K., Ranjan,R., Meena,A., Akhter,M.S., Yadav,B.K., Behari,M. and Saxena,R. Thrombin activatable fibrinolysis inhibitor gene polymorphisms are associated with antigenic levels in the Asian-Indian population but may not be a risk for stroke Br J Haematol (2008) 143, 581-588. PubMed Europe PubMed DOI M
Boffa,M.B., Maret,D., Hamill,J.D., Bastajian,N., Crainich,P., Jenny,N.S., Tang,Z., Macy,E.M., Tracy,R.P., Franco,R.F., Nesheim,M.E. and Koschinsky,M.L. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis Blood (2008) 111, 183-189. PubMed Europe PubMed DOI M
Bruno,N.E., Yano,Y., Takei,Y., Qin,L., Suzuki,T., Morser,J., D'Alessandro-Gabazza,C.N., Mizoguchi,A., Suzuki,K., Taguchi,O., Gabazza,E.C. and Sumida,Y. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency Thromb Haemost (2008) 100, 90-100. PubMed Europe PubMed DOI K
Buelens,K., Hillmayer,K., Compernolle,G., Declerck,P.J. and Gils,A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor Circ Res (2008) 102, 295-301. PubMed Europe PubMed DOI
Foley,J.H., Kim,P. and Nesheim,M.E. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis J Biol Chem (2008) 283, 8863-8867. PubMed Europe PubMed DOI PMC EPMC
Gils,A. Which carboxypeptidase determines the antifibrinolytic potential? J Thromb Haemost (2008) 6, 846-847. PubMed Europe PubMed DOI
Hillmayer,K., Ceresa,E., Vancraenenbroeck,R., Declerck,P.J. and Gils,A. Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor J Thromb Haemost (2008) 6, 1426-1428. PubMed Europe PubMed DOI
Hillmayer,K., Vancraenenbroeck,R., De Maeyer,M., Compernolle,G., Declerck,P.J. and Gils,A. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor J Thromb Haemost (2008) 6, 1892-1899. PubMed Europe PubMed DOI I
Kim,P.Y., Foley,J., Hsu,G., Kim,P.Y. and Nesheim,M.E. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma Anal Biochem (2008) 372, 32-40. PubMed Europe PubMed DOI A
Kim,P.Y., Kim,P.Y., Hoogendorn,H., Giles,A.R. and Nesheim,M.E. Activated thrombin-activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation J Thromb Haemost (2008) 6, 1600-1602. PubMed Europe PubMed DOI PMC EPMC
Leung,L.L., Myles,T., Nishimura,T., Song,J.J. and Robinson,W.H. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI) Mol Immunol (2008) 45, 4080-4083. PubMed Europe PubMed DOI
Marx,P.F., Brondijk,T.H., Plug,T., Romijn,R.A., Hemrika,W., Meijers,J.C. and Huizinga,E.G. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation Blood (2008) 112, 2803-2809. PubMed Europe PubMed DOI S I
Matthiessen,H.P., Willemse,J., Weber,A., Turecek,P.L., Deiteren,K., Hendriks,D., Ehrlich,H.J. and Schwarz,H.P. Ethanol dependence of alpha1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases Transfusion (2008) 48, 314-320. PubMed Europe PubMed DOI
Sanglas,L., Valnickova,Z., Arolas,J.L., Pallares,I., Guevara,T., Sola,M., Kristensen,T., Enghild,J.J., Aviles,F.X. and Gomis-Ruth,F.X. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis Mol Cell (2008) 31, 598-606. PubMed Europe PubMed DOI S
Soni,H., Sharma,A., Bhatt,S., Jain,M.R. and Patel,P.R. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats Pharmacology (2008) 82, 304-309. PubMed Europe PubMed DOI
Willemse,J.L., Polla,M., Olsson,T. and Hendriks,D.F. Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development Clin Chim Acta (2008) 387, 158-160. PubMed Europe PubMed DOI A
Willemse,J.L., Brouns,R., Heylen,E., De Deyn,P.P. and Hendriks,D.F. Carboxypeptidase U (TAFIa) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy J Thromb Haemost (2008) 6, 200-202. PubMed Europe PubMed DOI
Xu,C.W., Wang,L.L., Wu,X.B., Zhao,J.J., Du,Y.M. and Jiang,C.Y. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease] Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2008) 25, 438-442. PubMed Europe PubMed M

2007

Akatsu,H., Ishiguro,M., Ogawa,N., Kanesaka,T., Okada,N., Yamamoto,T., Campbell,W. and Okada,H. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal japanese population Microbiol Immunol (2007) 51, 507-517. PubMed Europe PubMed
Boffa,M.B. and Koschinsky,M.L. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles Clin Biochem (2007) 40, 431-442. PubMed Europe PubMed DOI V
Bunnage,M.E., Blagg,J., Steele,J., Owen,D.R., Allerton,C., McElroy,A.B., Miller,D., Ringer,T., Butcher,K., Beaumont,K., Evans,K., Gray,A.J., Holland,S.J., Feeder,N., Moore,R.S. and Brown,D.G. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis J Med Chem (2007) 50, 6095-6103. PubMed Europe PubMed DOI I
de Bruijne,E.L., Darwish Murad,S., de Maat,M.P., Tanck,M.W., Haagsma,E.B., van Hoek,B., Rosendaal,F.R., Janssen,H.L. and Leebeek,F.W. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis Thromb Haemost (2007) 97, 181-185. PubMed Europe PubMed DOI M
Dusse,L.M., Cooper,A.J. and Lwaleed,B.A. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia? Clin Chim Acta (2007) 378, 1-6. PubMed Europe PubMed DOI
Guimaraes,A.H., Laurens,N., Weijers,E.M., Koolwijk,P., van Hinsbergh,V.W. and Rijken,D.C. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells Arterioscler Thromb Vasc Biol (2007) 27, 2157-2162. PubMed Europe PubMed DOI
Islam,I., Bryant,J., May,K., Mohan,R., Yuan,S., Kent,L., Morser,J., Zhao,L., Vergona,R., White,K., Adler,M., Whitlow,M. and Buckman,B.O. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) Bioorg Med Chem Lett (2007) 17, 1349-1354. PubMed Europe PubMed DOI I
Ladenvall,C., Gils,A., Jood,K., Blomstrand,C., Declerck,P.J. and Jern,C. Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation Arterioscler Thromb Vasc Biol (2007) 27, 955-962. PubMed Europe PubMed DOI
Muto,Y., Suzuki,K., Iida,H. and Ishii,H. EF6265, a novel plasma carboxypeptidase B inhibitor, protects against renal dysfunction in rat thrombotic glomerulonephritis through enhancing fibrinolysis Nephron Exp Nephrol (2007) 106, e113-e121. PubMed Europe PubMed DOI I
Nishimura,T., Myles,T., Piliposky,A.M., Kao,P.N., Berry,G.J. and Leung,L.L. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo Blood (2007) 109, 1992-1997. PubMed Europe PubMed DOI PMC EPMC
Skeppholm,M., Wallen,N.H., Malmqvist,K., Kallner,A. and Antovic,J.P. Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome Thromb Res (2007) 121, 175-181. PubMed Europe PubMed DOI A
Vairaktaris,E., Yapijakis,C., Nkenke,E., Vassiliou,S., Vylliotis,A., Nixon,A.M., Derka,S., Ragos,V., Spyridonidou,S., Tsigris,C., Neukam,F.W. and Patsouris,E. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer Am J Hematol (2007) 82, 1010-1012. PubMed Europe PubMed DOI M
Valnickova,Z., Thogersen,I.B., Potempa,J. and Enghild,J.J. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase J Biol Chem (2007) 282, 3066-3076. PubMed Europe PubMed DOI
Valnickova,Z., Thogersen,I.B., Potempa,J. and Enghild,J.J. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate: reply to a rebuttal J Thromb Haemost (2007) 5, 1336-1337. PubMed Europe PubMed DOI
Walker,J.B. and Bajzar,L. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors J Thromb Haemost (2007) 5, 1257-1264. PubMed Europe PubMed DOI
Wang,X., Smith,P.L., Hsu,M.Y., Tamasi,J.A., Bird,E. and Schumacher,W.A. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis J Thromb Thrombolysis (2007) 23, 41-49. PubMed Europe PubMed DOI K
Wang,Y.X., da Cunha,V., Vincelette,J., Zhao,L., Nagashima,M., Kawai,K., Yuan,S., Emayan,K., Islam,I., Hosoya,J., Sullivan,M.E., Dole,W.P., Morser,J., Buckman,B.O. and Vergona,R. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis Thromb Haemost (2007) 97, 54-61. PubMed Europe PubMed DOI I
Wang,Y.X., Zhao,L., Nagashima,M., Vincelette,J., Sukovich,D., Li,W., Subramanyam,B., Yuan,S., Emayan,K., Islam,I., Hrvatin,P., Bryant,J., Light,D.R., Vergona,R., Morser,J. and Buckman,B.O. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization Thromb Haemost (2007) 97, 45-53. PubMed Europe PubMed DOI I
Willemse,J.L., Matus,V., Heylen,E., Mezzano,D. and Hendriks,D.F. Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin-activable fibrinolysis inhibitor) activity-based assays J Thromb Haemost (2007) 5, 872-875. PubMed Europe PubMed DOI A M
Willemse,J.L., Heylen,E. and Hendriks,D.F. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal J Thromb Haemost (2007) 5, 1334-1336. PubMed Europe PubMed DOI

2006

Bertina,R.M., van Tilburg,N.H., Haverkate,F., Bouma,B.N., von dem Borne,P.A., Meijers,J.C., Campbell,W., Eaton,D., Hendriks,D.F. and Willemse,J.L. Discovery of thrombin activatable fibrinolysis inhibitor (TAFI) J Thromb Haemost (2006) 4, 256-257. PubMed Europe PubMed DOI
Bouma,B.N. and Mosnier,L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) - how does thrombin regulate fibrinolysis? Ann Med (2006) 38, 378-388. PubMed Europe PubMed DOI V
[YEAR:4-4-2006]Ceresa,E., Van de Borne,K., Peeters,M., Lijnen,H.R., Declerck,P.J. and Gils,A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant J Biol Chem (4-4-2006) 281, 15878-15883. PubMed Europe PubMed DOI
Fujimoto,H., Gabazza,E.C., Taguchi,O., Nishii,Y., Nakahara,H., Bruno,N.E., D'Alessandro-Gabazza,C.N., Kasper,M., Yano,Y., Nagashima,M., Morser,J., Broze,G.J., Suzuki,K. and Adachi,Y. Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis Am J Pathol (2006) 168, 1086-1096. PubMed Europe PubMed DOI PMC EPMC K
Hillmayer,K., Macovei,A., Pauwels,D., Compernolle,G., Declerck,P.J. and Gils,A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI J Thromb Haemost (2006) 4, 2470-2477. PubMed Europe PubMed DOI
Martini,C.H., Brandts,A., de Bruijne,E.L., van Hylckama Vlieg,A., Leebeek,F.W., Lisman,T. and Rosendaal,F.R. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis Br J Haematol (2006) 134, 92-94. PubMed Europe PubMed DOI M
[YEAR:7-9-2006]Mosnier,L.O. and Bouma,B.N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis Arterioscler Thromb Vasc Biol (7-9-2006) 26, 2445-2453. PubMed Europe PubMed DOI V
[YEAR:7-2-2006]Valnickova,Z., Christensen,T., Skottrup,P., Thogersen,I.B., Hojrup,P. and Enghild,J.J. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation Biochemistry (7-2-2006) 45, 1525-1535. PubMed Europe PubMed DOI
Willemse,J.L. and Hendriks,D.F. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge Clin Chem (2006) 52, 30-36. PubMed Europe PubMed DOI

2005

Cruden,N.L., Lawes,L., Masson,P., Robinson,S.D., Ludlam,C.A. and Newby,D.E. Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood J Thromb Haemost (2005) 3, 2351-2353. PubMed Europe PubMed DOI
Do,Y.H., Gifford-Moore,D.S., Beight,D.W., Rathnachalam,R., Klimkowski,V.J., Warshawsky,A.M. and Lu,D. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives Thromb Res (2005) 116, 265-271. PubMed Europe PubMed DOI I
Frere,C., Morange,P.E., Saut,N., Tregouet,D.A., Grosley,M., Beltran,J., Juhan-Vague,I. and Alessi,M.C. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact Thromb Haemost (2005) 94, 373-379. PubMed Europe PubMed DOI
Guimaraes,A.H., Bertina,R.M. and Rijken,D.C. A new functional assay of thrombin activatable fibrinolysis inhibitor J Thromb Haemost (2005) 3, 1284-1292. PubMed Europe PubMed DOI A
He,L., Asai,S., Kawamura,T., Kimbara,N., Tada,T., Okada,H. and Okada,N. Hepatitis induced by an IgM monoclonal antibody against procarboxypeptidase R Microbiol Immunol (2005) 49, 373-380. PubMed Europe PubMed
[YEAR:8-7-2005]Leebeek,F.W., Goor,M.P., Guimaraes,A.H., Brouwers,G.J., Maat,M.P., Dippel,D.W. and Rijken,D.C. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke J Thromb Haemost (8-7-2005) 3, 2211-2218. PubMed Europe PubMed DOI
Mao,S.S., Holahan,M.A., Bailey,C., Wu,G., Colussi,D., Carroll,S.S. and Cook,J.J. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice Blood Coagul Fibrinolysis (2005) 16, 407-415. PubMed Europe PubMed K
Marx,P.F., Havik,S.R., Bouma,B.N. and Meijers,J.C. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor J Thromb Haemost (2005) 3, 1293-1300. PubMed Europe PubMed DOI
Nesheim,M. and Bajzar,L. The discovery of TAFI J Thromb Haemost (2005) 3, 2139-2146. PubMed Europe PubMed DOI
Post,M.S., Leurs,J.R., Van der Mooren,M.J., Van Baal,W.M., Hendriks,D.F., Stehouwer,C.D. and Kenemans,P. Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study Thromb Haemost (2005) 93, 620-622. PubMed Europe PubMed DOI
[YEAR:15-11-2005]Renckens,R., Roelofs,J.J., ter Horst,S.A., van 't Veer,C., Havik,S.R., Florquin,S., Wagenaar,G.T., Meijers,J.C. and van der Poll,T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice J Immunol (15-11-2005) 175, 6764-6771. PubMed Europe PubMed K
Zimonjic,D.B., Liu,J., Xu,W.H., Zhou,X., Popescu,N.C. and Shi,G.P. Assignment of murine placental cathepsin R to mouse chromosome bands 13B2-B3 by fluorescence in situ hybridization Cytogenet Genome Res (2005) 111, 96-96. PubMed Europe PubMed DOI

2004

Akatsu,H., Yamagata,H., Chen,Y., Miki,T., Kamino,K., Takeda,M., Campbell,W., Kondo,I., Kosaka,K., Yamamoto,T. and Okada,H. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction Br J Haematol (2004) 127, 440-447. PubMed Europe PubMed DOI M
Antovic,J.P., Schulman,S., An,S.S., Greenfield,R.S. and Blomback,M. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease? Scand J Clin Lab Invest (2004) 64, 745-751. PubMed Europe PubMed DOI
[YEAR:1-10-2004]Asai,S., Sato,T., Tada,T., Miyamoto,T., Kimbara,N., Motoyama,N., Okada,H. and Okada,N. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice J Immunol (1-10-2004) 173, 4669-4674. PubMed Europe PubMed K
Bajzar,L., Jain,N., Wang,P. and Walker,J.B. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis Crit Care Med (2004) 32, S320-S324. PubMed Europe PubMed
Bouma,B.N. and Meijers,J.C. New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R) Semin Hematol (2004) 41, 13-19. PubMed Europe PubMed
Guimaraes,A.H. and Rijken,D.C. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model Thromb Haemost (2004) 91, 473-479. PubMed Europe PubMed DOI
Guimaraes,A.H., Barrett-Bergshoeff,M.M., Gils,A., Declerck,P.J. and Rijken,D.C. Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis J Thromb Haemost (2004) 2, 780-784. PubMed Europe PubMed DOI
Hendriks,D.F. Carboxypeptidase U [ISSN:0-12-079610-4] (2004) 2, 825-828. V
Kremer Hovinga,J.A., Franco,R.F., Zago,M.A., ten Cate,H., Westendorp,R.G. and Reitsma,P.H. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease J Thromb Haemost (2004) 2, 54-57. PubMed Europe PubMed DOI M
Leurs,J., Nerme,V., Sim,Y. and Hendriks,D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism J Thromb Haemost (2004) 2, 416-423. PubMed Europe PubMed DOI
Malyszko,J., Malyszko,J.S., Hryszko,T. and Mysliwiec,M. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy Thromb Haemost (2004) 91, 480-486. PubMed Europe PubMed DOI
Maret,D., Boffa,M.B., Brien,D.F., Nesheim,M.E. and Koschinsky,M.L. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor J Thromb Haemost (2004) 2, 1969-1979. PubMed Europe PubMed DOI
Marx,P.F. Thrombin-activatable fibrinolysis inhibitor Curr Med Chem (2004) 11, 2335-2348. PubMed Europe PubMed V
[YEAR:20-2-2004]Marx,P.F., Havik,S.R., Marquart,J.A., Bouma,B.N. and Meijers,J.C. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor J Biol Chem (20-2-2004) 279, 6620-6628. PubMed Europe PubMed DOI
Mousa,H.A., Downey,C., Alfirevic,Z. and Toh,C.H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy Thromb Haemost (2004) 92, 1025-1031. PubMed Europe PubMed DOI
[YEAR:3-5-2004]Nantermet,P.G., Barrow,J.C., Lindsley,S.R., Young,M., Mao,S.S., Carroll,S., Bailey,C., Bosserman,M., Colussi,D., McMasters,D.R., Vacca,J.P. and Selnick,H.G. Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group Bioorg Med Chem Lett (3-5-2004) 14, 2141-2145. PubMed Europe PubMed DOI
[YEAR:15-7-2004]Neill,E.K., Stewart,R.J., Schneider,M.M. and Nesheim,M.E. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma Anal Biochem (15-7-2004) 330, 332-341. PubMed Europe PubMed DOI A
Reijerkerk,A., Meijers,J.C., Havik,S.R., Bouma,B.N., Voest,E.E. and Gebbink,M.F. Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice J Thromb Haemost (2004) 2, 769-779. PubMed Europe PubMed DOI K
[YEAR:8-1-2004]Schneider,M., Brufatto,N., Neill,E. and Nesheim,M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin J Biol Chem (8-1-2004) 279, 13340-13345. PubMed Europe PubMed DOI
Stromqvist,M., Hansson,L., Andersson,J.O., Johansson,T., Edlund,M., Enoksson,M., Goossens,F., Scharpe,S. and Hendriks,D. Properties of recombinant human plasma procarboxypeptidase U produced in mammalian and insect cells Clin Chim Acta (2004) 347, 49-59. PubMed Europe PubMed DOI E
Suzuki,K., Muto,Y., Fushihara,K., Kanemoto,K., Iida,H., Sato,E., Kikuchi,C., Matsushima,T., Kato,E., Nomoto,M., Yoshioka,S. and Ishii,H. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxypho sphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B J Pharmacol Exp Ther (2004) 309, 607-615. PubMed Europe PubMed DOI
[YEAR:2-7-2004]Walker,J.B. and Bajzar,L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability J Biol Chem (2-7-2004) 279, 27896-27904. PubMed Europe PubMed DOI

2003

Antovic,J.P. and Antovic,A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay Thromb Haemost (2003) 90, 620-627. PubMed Europe PubMed DOI
[YEAR:4-12-2003]Barrow,J.C., Nantermet,P.G., Stauffer,S.R., Ngo,P.L., Steinbeiser,M.A., Mao,S.S., Carroll,S.S., Bailey,C., Colussi,D., Bosserman,M., Burlein,C., Cook,J.J., Sitko,G., Tiller,P.R., Miller-Stein,C.M., Rose,M., McMasters,D.R., Vacca,J.P. and Selnick,H.G. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics J Med Chem (4-12-2003) 46, 5294-5297. PubMed Europe PubMed DOI
[YEAR:20-9-2003]Bouma,B.N. and Mosnier,L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis Pathophysiol Haemost Thromb (20-9-2003) 33, 375-381. PubMed Europe PubMed DOI V
Brouwers,G.J., Leebeek,F.W., Tanck,M.W., Wouter Jukema,J., Kluft,C. and de Maat,M.P. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris Thromb Haemost (2003) 90, 92-100. PubMed Europe PubMed DOI M
Colucci,M., Binetti,B.M., Branca,M.G., Clerici,C., Morelli,A., Semeraro,N. and Gresele,P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis Hepatology (2003) 38, 230-237. PubMed Europe PubMed DOI
Falk,K., Bjorquist,P., Falk,P., Hedgren,M., Ivarsson,M.L., Lanne,B., Panfilov,O. and Holmdahl,L. Antifibrinolytic proCPU is present in the peritoneal cavity during surgery Scand J Clin Lab Invest (2003) 63, 287-296. PubMed Europe PubMed DOI
[YEAR:15-6-2003]Fujimoto,H., Gabazza,E.C., Hataji,O., Yuda,H., D'Alessandro-Gabazza,C.N., Nakano,M., Franco,O.E., Hayashi,T., Suzuki,K., Adachi,Y. and Taguchi,O. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease Am J Respir Crit Care Med (15-6-2003) 167, 1687-1694. PubMed Europe PubMed DOI
Knoefler,R., Ludwig,K., Kostka,H., Kuhlisch,E., Siegert,G. and Suttorp,M. The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients Semin Thromb Hemost (2003) 29, 575-583. PubMed Europe PubMed DOI M
Leurs,J., Wissing,B.M., Nerme,V., Schatteman,K., Bjorquist,P. and Hendriks,D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma Thromb Haemost (2003) 89, 264-271. PubMed Europe PubMed DOI
[YEAR:15-6-2003]Mosnier,L.O., Buijtenhuijs,P., Marx,P.F., Meijers,J.C. and Bouma,B.N. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets Blood (15-6-2003) 101, 4844-4846. PubMed Europe PubMed DOI
[YEAR:14-2-2003]Muto,Y., Suzuki,K., Sato,E. and Ishii,H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats Eur J Pharmacol (14-2-2003) 461, 181-189. PubMed Europe PubMed DOI I
[YEAR:19-12-2003]Myles,T., Nishimura,T., Yun,T.H., Nagashima,M., Morser,J., Patterson,A.J., Pearl,R.G. and Leung,L.L. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation J Biol Chem (19-12-2003) 278, 51059-51067. PubMed Europe PubMed DOI
Shimomura,Y., Kawamura,T., Komura,H., Campbell,W., Okada,N. and Okada,H. Modulation of procarboxypeptidase R (ProCPR) activation by complementary peptides to thrombomodulin Microbiol Immunol (2003) 47, 241-245. PubMed Europe PubMed
Toh,C.H. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction Blood Coagul Fibrinolysis (2003) 14 Suppl 1, S69-S71. PubMed Europe PubMed DOI
[YEAR:14-3-2003]Walker,J.B., Hughes,B., James,I., Haddock,P., Kluft,C. and Bajzar,L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro J Biol Chem (14-3-2003) 278, 8913-8921. PubMed Europe PubMed DOI I
Wu,C., Dong,N., da Cunha,V., Martin-McNulty,B., Tran,K., Nagashima,M., Wu,Q., Morser,J. and Wang,Y.X. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs Thromb Haemost (2003) 90, 414-421. PubMed Europe PubMed DOI
[YEAR:22-8-2003]Zhao,L., Buckman,B., Seto,M., Morser,J. and Nagashima,M. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity J Biol Chem (22-8-2003) 278, 32359-32366. PubMed Europe PubMed DOI

2002

Antovic,J.P., Rafik Hamad,R., Antovic,A., Blomback,M. and Bremme,K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost (2002) 88, 644-647. PubMed Europe PubMed DOI
[YEAR:16-8-2002]Barbosa Pereira,P.J., Segura-Martin,S., Oliva,B., Ferrer-Orta,C., Aviles,F.X., Coll,M., Gomis-Ruth,F.X. and Vendrell,J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI) J Mol Biol (16-8-2002) 321, 537-547. PubMed Europe PubMed DOI S
Campbell,W.D., Lazoura,E., Okada,N. and Okada,H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N Microbiol Immunol (2002) 46, 131-134. PubMed Europe PubMed
Colucci,M., Pentimone,A., Binetti,B.M., Cramarossa,M., Piro,D. and Semeraro,N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin Thromb Haemost (2002) 88, 282-287. PubMed Europe PubMed
Kawamura,T., Okada,N. and Okada,H. Elastase from activated human neutrophils activates procarboxypeptidase R Microbiol Immunol (2002) 46, 225-230. PubMed Europe PubMed
Komura,H., Obata,K., Campbell,W., Yumoto,M., Shimomura,Y., Katsuya,H., Okada,N. and Okada,H. Effect of anticoagulants in colorimetric assay for basic carboxypeptidases Microbiol Immunol (2002) 46, 115-117. PubMed Europe PubMed A
Komura,H., Shimomura,Y., Yumoto,M., Katsuya,H., Okada,N. and Okada,H. Heat stability of carboxypeptidase R of experimental animals Microbiol Immunol (2002) 46, 217-223. PubMed Europe PubMed
[YEAR:29-1-2002]Marx,P.F., Bouma,B.N. and Meijers,J.C. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor Biochemistry (29-1-2002) 41, 1211-1216. PubMed Europe PubMed DOI
[YEAR:28-5-2002]Marx,P.F., Dawson,P.E., Bouma,B.N. and Meijers,J.C. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor Biochemistry (28-5-2002) 41, 6688-6696. PubMed Europe PubMed DOI
Post,M.S., Hendriks,D.F., Van der Mooren,M.J., Van Baal,W.M., Leurs,J.R., Emeis,J.J., Kenemans,P. and Stehouwer,C.D. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women J Intern Med (2002) 251, 245-251. PubMed Europe PubMed DOI
[YEAR:22-3-2002]Schneider,M., Nagashima,M., Knappe,S., Zhao,L., Morser,J. and Nesheim,M. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation J Biol Chem (22-3-2002) 277, 9944-9951. PubMed Europe PubMed DOI
Schneider,M., Boffa,M., Stewart,R., Rahman,M., Koschinsky,M. and Nesheim,M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme J Biol Chem (2002) 277, 1021-1030. PubMed Europe PubMed DOI M
Swaisgood,C.M., Schmitt,D., Eaton,D. and Plow,E.F. In vivo regulation of plasminogen function by plasma carboxypeptidase B J Clin Invest (2002) 110, 1275-1282. PubMed Europe PubMed DOI PMC EPMC K

2001

[YEAR:1-3-2001]Bouma,B.N., Marx,P.F., Mosnier,L.O. and Meijers,J.C.M. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) Thromb Res (1-3-2001) 101, 329-354. PubMed Europe PubMed DOI
[YEAR:15-9-2001]Brouwers,G.J., Vos,H.L., Leebeek,F.W.G., Bulk,S., Schneider,M., Boffa,M., Koschinsky,M., van Tilburg,N.H., Nesheim,M.E., Bertina,R.M. and Garcia,E.B.G. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels Blood (15-9-2001) 98, 1992-1993. PubMed Europe PubMed DOI M
Campbell,W., Okada,N. and Okada,H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis Immunol Rev (2001) 180, 162-167. PubMed Europe PubMed DOI
Colucci,M., D'Aprile,A.M., Italia,A., Gresele,P., Morser,J. and Semeraro,N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA Thromb Haemost (2001) 85, 661-666. PubMed Europe PubMed
Henry,M., Aubert,H., Morange,P.E., Nanni,I., Alessi,M.C., Tiret,L. and Juhan-Vague,I. Identification of polymorphisms in the promoter and the 3 ' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled Blood (2001) 97, 2053-2058. PubMed Europe PubMed DOI M
Koschinsky,M.L., Boffa,M.B., Nesheim,M.E., Zinman,B., Hanley,A.J.G., Harris,S.B., Cao,H. and Hegele,R.A. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure Clin Genet (2001) 60, 345-349. PubMed Europe PubMed DOI M
Matsumoto,A., Motozaki,K., Seki,T., Sasaki,R. and Kawabe,T. Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids Neurosci Res (2001) 39, 313-317. PubMed Europe PubMed DOI
Matsumoto,A., Itoh,K., Seki,T., Motozaki,K. and Matsuyama,S. Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons Eur J Neurosci (2001) 13, 1653-1657. PubMed Europe PubMed DOI
Mosnier,L.O., Meijers,J.C. and Bouma,B.N. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin Thromb Haemost (2001) 85, 5-11. PubMed Europe PubMed
Mosnier,L.O., Lisman,T., van den Berg,H.M., Nieuwenhuis,H.K., Meijers,J.C. and Bouma,B.N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration Thromb Haemost (2001) 86, 1035-1039. PubMed Europe PubMed
Mosnier,L.O., Meijers,J.C. and Bouma,B.N. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis Thromb Haemost (2001) 86, 1040-1046. PubMed Europe PubMed
Mosnier,L.O., Elisen,M.G., Bouma,B.N. and Meijers,J.C. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and down regulation of TAFI activation Thromb Haemost (2001) 86, 1057-1064. PubMed Europe PubMed
Schatteman,K.A., Goossens,F.J., Leurs,J., Kasahara,Y., Scharpe,S.S. and Hendriks,D.F. Fast homogeneous assay for plasma procarboxypeptidase U Clin Chem Lab Med (2001) 39, 806-810. PubMed Europe PubMed DOI A
Stromqvist,M., Schatteman,K., Leurs,J., Verkerk,R., Andersson,J.O., Johansson,T., Scharpe,S. and Hendriks,D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma Thromb Haemost (2001) 85, 12-17. PubMed Europe PubMed A
Tregouet,D.A., Aubert,H., Henry,M., Morange,P., Visvikis,S., Juhan-Vague,I. and Tiret,L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms Hum Genet (2001) 109, 191-197. PubMed Europe PubMed DOI M
van Gorp,E.C., Minnema,M.C., Suharti,C., Mairuhu,A.T., Brandjes,D.P., ten Cate,H., Hack,C.E. and Meijers,J.C. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever Br J Haematol (2001) 113, 94-99. PubMed Europe PubMed DOI

2000

Bajzar,L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway Arterioscler Thromb Vasc Biol (2000) 20, 2511-2518. PubMed Europe PubMed V
Chetaille,P., Alessi,M.C., Kouassi,D., Morange,P.E. and Juhan-Vague,I. Plasma TAFI antigen variations in healthy subjects Thromb Haemost (2000) 83, 902-905. PubMed Europe PubMed
Marx,P.F., Wagenaar,G.T., Reijerkerk,A., Tiekstra,M.J., van Rossum,A.G., Gebbink,M.F. and Meijers,J.C. Characterization of mouse thrombin-activatable fibrinolysis inhibitor Thromb Haemost (2000) 83, 297-303. PubMed Europe PubMed
[YEAR:28-4-2000]Marx,P.F., Hackeng,T.M., Dawson,P.E., Griffin,J.H., Meijers,J.C. and Bouma,B.N. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage J Biol Chem (28-4-2000) 275, 12410-12415. PubMed Europe PubMed DOI
Matsumoto,A., Itoh,K. and Matsumoto,R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus Eur J Neurosci (2000) 12, 227-238. PubMed Europe PubMed DOI
Meijers,J.C., Oudijk,E.J., Mosnier,L.O., Bos,R., Bouma,B.N., Nieuwenhuis,H.K. and Fijnheer,R. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia Br J Haematol (2000) 108, 518-523. PubMed Europe PubMed DOI
[YEAR:15-5-2000]Nagashima,M., Werner,M., Wang,M., Zhao,L., Light,D.R., Pagila,R., Morser,J. and Verhallen,P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model Thromb Res (15-5-2000) 98, 333-342. PubMed Europe PubMed DOI
[YEAR:15-7-2000]Sato,T., Miwa,T., Akatsu,H., Matsukawa,N., Obata,K., Okada,N., Campbell,W. and Okada,H. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not J Immunol (15-7-2000) 165, 1053-1058. PubMed Europe PubMed
[YEAR:25-2-2000]Schatteman,K.A., Goossens,F.J., Scharpe,S.S. and Hendriks,D.F. Proteolytic activation of purified human procarboxypeptidase U Clin Chim Acta (25-2-2000) 292, 25-40. PubMed Europe PubMed DOI
Silveira,A., Schatteman,K., Goossens,F., Moor,E., Scharpe,S., Stromqvist,M., Hendriks,D. and Hamsten,A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease Thromb Haemost (2000) 84, 364-368. PubMed Europe PubMed
[YEAR:24-11-2000]Stewart,R.J., Fredenburgh,J.C., Rischke,J.A., Bajzar,L. and Weitz,J.I. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator J Biol Chem (24-11-2000) 275, 36612-36620. PubMed Europe PubMed DOI

1999

[YEAR:18-5-1999]Boffa,M.B., Reid,T.S., Joo,E., Nesheim,M.E. and Koschinsky,M.L. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B) Biochemistry (18-5-1999) 38, 6547-6558. PubMed Europe PubMed DOI
Guo,X., Morioka,A., Kaneko,Y., Okada,N., Obata,K., Nomura,T., Campbell,W. and Okada,H. Arginine carboxypeptidase (CPR) in human plasma determined with sandwich ELISA Microbiol Immunol (1999) 43, 691-698. PubMed Europe PubMed
[YEAR:3-12-1999]Mao,S.S., Cooper,C.M., Wood,T., Shafer,J.A. and Gardell,S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans J Biol Chem (3-12-1999) 274, 35046-35052. PubMed Europe PubMed DOI
Schatteman,K.A., Goossens,F.J., Scharpe,S.S., Neels,H.M. and Hendriks,D.F. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma Clin Chem (1999) 45, 807-813. PubMed Europe PubMed A
Schatteman,K.A., Goossens,F.J., Scharpe,S.S. and Hendriks,D.F. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis Thromb Haemost (1999) 82, 1718-1721. PubMed Europe PubMed

1998

Bajzar,L., Nesheim,M., Morser,J. and Tracy,P.B. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor J Biol Chem (1998) 273, 2792-2798. PubMed Europe PubMed DOI
[YEAR:23-1-1998]Boffa,M.B., Wang,W., Bajzar,L. and Nesheim,M.E. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties J Biol Chem (23-1-1998) 273, 2127-2135. PubMed Europe PubMed DOI I
Nesheim,M. Fibrinolysis and the plasma carboxypeptidase Curr Opin Hematol (1998) 5, 309-313. PubMed Europe PubMed V
[YEAR:16-10-1998]Valnickova,Z. and Enghild,J.J. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin J Biol Chem (16-10-1998) 273, 27220-27224. PubMed Europe PubMed DOI
[YEAR:16-10-1998]Wang,W., Boffa,M.B., Bajzar,L., Walker,J.B. and Nesheim,M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor J Biol Chem (16-10-1998) 273, 27176-27181. PubMed Europe PubMed DOI

1997

Nesheim,M., Wang,W., Boffa,M., Nagashima,M., Morser,J. and Bajzar,L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis Thromb Haemost (1997) 78, 386-391. PubMed Europe PubMed
Plow,E.F., Allampallam,K. and Redlitz,A. The plasma carboxypeptidases and the regulation of the plasminogen system Trend.Cardiovasc.Med. (1997) 7, 71-75. PubMed Europe PubMed DOI
Sakharov,D.V., Plow,E.F. and Rijken,D.C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B J Biol Chem (1997) 272, 14477-14482. PubMed Europe PubMed DOI

1996

Broze,G.J., Jr. and Higuchi,D.A. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma Blood (1996) 88, 3815-3823. PubMed Europe PubMed
Broze,G.J., Jr. Thrombin-dependent inhibition of fibrinolysis Curr Opin Hematol (1996) 3, 390-394. PubMed Europe PubMed
Valnickova,Z., Thogersen,I.B., Christensen,S., Chu,C.T., Pizzo,S.V. and Enghild,J.J. Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein J Biol Chem (1996) 271, 12937-12943. PubMed Europe PubMed DOI
Vanhoof,G., Wauters,J., Schatteman,K., Hendriks,D., Goossens,F., Bossuyt,P. and Scharpe,S. The gene for human carboxypeptidase U (CPU) - A proposed novel regulator of plasminogen activation - Maps to 13q14.11 Genomics (1996) 38, 454-455. PubMed Europe PubMed DOI

1995

[YEAR:16-6-1995]Bajzar,L., Manuel,R. and Nesheim,M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor J Biol Chem (16-6-1995) 270, 14477-14484. PubMed Europe PubMed DOI
Redlitz,A., Tan,A.K., Eaton,D.L. and Plow,E.F. Plasma carboxypeptidases as regulators of the plasminogen system J Clin Invest (1995) 96, 2534-2538. PubMed Europe PubMed DOI PMC EPMC
Tan,A.K. and Eaton,D.L. Activation and characterization of procarboxypeptidase B from human plasma Biochemistry (1995) 34, 5811-5816. PubMed Europe PubMed

1994

Wang,W., Hendriks,D.F. and Scharpe,S.S. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen J Biol Chem (1994) 269, 15937-15944. PubMed Europe PubMed

1992

Hendriks,D., Wang,W., Van Sande,M. and Scharpe,S. Human serum carboxypeptidase U: a new kininase? Agents Actions Suppl (1992) 38, 407-413. PubMed Europe PubMed
Tsai,S.P. and Drayna,D. The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13 Genomics (1992) 14, 549-550. PubMed Europe PubMed DOI

1991

Eaton,D.L., Malloy,B.E., Tsai,S.P., Henzel,W. and Drayna,D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma J Biol Chem (1991) 266, 21833-21838. PubMed Europe PubMed

1990

Hendriks,D., Wang,W., Scharpe,S., Lommaert,M.P. and Van Sande,M. Purification and characterization of a new arginine carboxypeptidase in human serum Biochim Biophys Acta (1990) 1034, 86-92. PubMed Europe PubMed DOI I

1989

[YEAR:15-8-1989]Campbell,W. and Okada,H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits Biochem Biophys Res Commun (15-8-1989) 162, 933-939. PubMed Europe PubMed
Hendriks,D., Scharpe,S., Van Sande,M. and Lommaert,M.P. A labile enzyme in fresh human serum interferes with the assay of carboxypeptidase N Clin Chem (1989) 35, 177-177. PubMed Europe PubMed
Hendriks,D., Scharpe,S., Van Sande,M. and Lommaert,M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N J Clin Chem Clin Biochem (1989) 27, 277-285. PubMed Europe PubMed

1988

Hendriks,D., Soons,J., Scharpe,S., Wevers,R., Van Sande,M. and Holmquist,B. Identification of the carboxypeptidase responsible for the post-synthetic modification of creatine kinase in human serum Clin Chim Acta (1988) 172, 253-260. PubMed Europe PubMed

1977

[YEAR:1-5-1977]Marinkovic,D.V., Marinkovic,J.N., Erdos,E.G. and Robinson,C.J. Purification of carboxypeptidase B from human pancreas Biochem J (1-5-1977) 163, 253-260. PubMed Europe PubMed PMC EPMC